Remimazolam (original) (raw)
Remimazolam ist ein Arzneistoff aus der Gruppe der Benzodiazepine. Remimazolam wurde in Japan (als Anerem) im Januar 2020 zur allgemeinen Sedierung und in den USA und der EU (als Byfavo) im Juli 2020 bzw. März 2021 zur prozeduralen Kurzzeitsedierung (bei Verfahren, die bis zu 30 Minuten dauern) zugelassen. Es wird parenteral angewendet in Form des Benzolsulfonsäure-Salzes, Remimazolambesilat.
| Property | Value |
|---|---|
| dbo:abstract | Remimazolam ist ein Arzneistoff aus der Gruppe der Benzodiazepine. Remimazolam wurde in Japan (als Anerem) im Januar 2020 zur allgemeinen Sedierung und in den USA und der EU (als Byfavo) im Juli 2020 bzw. März 2021 zur prozeduralen Kurzzeitsedierung (bei Verfahren, die bis zu 30 Minuten dauern) zugelassen. Es wird parenteral angewendet in Form des Benzolsulfonsäure-Salzes, Remimazolambesilat. (de) Remimazolam, sold under the brand name Byfavo, is a medication for the induction and maintenance of procedural sedation in adults for invasive diagnostic or surgical procedures lasting 30 minutes or less. is a benzodiazepine drug, developed by in collaboration with several regional licensees as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in the induction of anesthesia and conscious sedation for minor invasive procedures. Remimazolam was found to have both a more rapid onset and a shorter duration than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications. The most common side effects for procedural sedation include low blood pressure, high blood pressure, diastolic hypertension, systolic hypertension, low blood oxygen level, and diastolic hypotension. Remimazolam was approved for medical use in the United States in July 2020, and in the European Union in March 2021. (en) Il remimazolam è uno psicofarmaco appartenente alla categoria delle ; Il farmaco è stato sviluppato da PAION AG in collaborazione con diversi licenziatari regionali come alternativa al midazolam a breve durata d'azione, per l'uso nell'induzione dell'anestesia e nella sedazione cosciente per procedure invasive minori. È stato riscontrato che il remimazolam ha sia un inizio più rapido che una durata più breve rispetto al midazolam; inoltre studi clinici sull'uomo hanno mostrato un tempo di recupero più rapido e una farmacocinetica prevedibile e coerente, suggerendo alcuni vantaggi rispetto ai farmaci esistenti per queste applicazioni. Remimazolam è stato approvato dalla FDA per uso medico negli Stati Uniti nel luglio 2020, e nell'Unione Europea nel marzo 2021. (it) Ремимазолам — лекарственное средство группы бензодиазепинов. Одобрен для применения: Япония (2020), США (2020) (ru) |
| dbo:alternativeName | Byfavo (en) |
| dbo:casNumber | 308242-62-8 |
| dbo:chEMBL | 4297526 |
| dbo:drugbank | DB12404 |
| dbo:fdaUniiCode | 7V4A8U16MB |
| dbo:kegg | D10194 D11788 |
| dbo:pubchem | 9867812 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Remimazolam.svg?width=300 |
| dbo:wikiPageExternalLink | https://druginfo.nlm.nih.gov/drugportal/name/remimazolam%7Cpublisher= |
| dbo:wikiPageID | 31282410 (xsd:integer) |
| dbo:wikiPageLength | 14669 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1120555872 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Benzodiazepine dbr:Hypertension dbr:Research_Triangle_Park dbr:United_States_National_Library_of_Medicine dbr:Intravenous_therapy dbc:Bromoarenes dbc:GABAA_receptor_positive_allosteric_modulators dbc:Methyl_esters dbr:GlaxoSmithKline dbc:Imidazobenzodiazepines dbr:Clinical_trial dbr:Committee_for_Medicinal_Products_for_Human_Use dbr:European_Medicines_Agency dbr:Food_and_Drug_Administration dbr:North_Carolina dbc:2-Pyridyl_compounds dbr:Hypotension dbr:Hypoxia_(medical) dbr:Midazolam dbr:Medication dbr:Procedural_sedation_and_analgesia dbr:Systolic_hypertension dbr:PAION_AG |
| dbp:atcPrefix | N05 (en) |
| dbp:atcSuffix | CD14 (en) |
| dbp:br | 1 (xsd:integer) |
| dbp:c | 21 (xsd:integer) |
| dbp:casNumber | 308242 (xsd:integer) |
| dbp:chembl | 4297526 (xsd:integer) |
| dbp:chemspiderid | 8043503 (xsd:integer) |
| dbp:dailymedid | Remimazolam (en) |
| dbp:drugbank | DB12404 (en) |
| dbp:h | 19 (xsd:integer) |
| dbp:index2Label | as salt (en) |
| dbp:iupacName | methyl 3-[-8-bromo-1-methyl-6--4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate (en) |
| dbp:kegg | D10194 (en) D11788 (en) |
| dbp:legalCa | Schedule IV (en) |
| dbp:legalDe | Anlage III (en) |
| dbp:legalEu | Rx-only (en) |
| dbp:legalUk | PSA (en) |
| dbp:legalUs | Rx-only (en) |
| dbp:licenceEu | yes (en) |
| dbp:n | 4 (xsd:integer) |
| dbp:o | 2 (xsd:integer) |
| dbp:pubchem | 9867812 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Intravenous_therapy |
| dbp:smiles | COCCC[C@@H]1N=Cc2ccccc2-n2ccnc21 (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | CYHWMBVXXDIZNZ-KRWDZBQOSA-N (en) |
| dbp:synonyms | CNS-7056 (en) |
| dbp:tradename | Byfavo (en) |
| dbp:unii | 7 (xsd:integer) |
| dbp:verifiedfields | changed (en) |
| dbp:verifiedrevid | 451607085 (xsd:integer) |
| dbp:watchedfields | changed (en) |
| dbp:width | 222 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Cite_web dbt:GABAAR_PAMs dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Stdinchicite dbt:Drugs.com dbt:Benzodiazepines dbt:ClinicalTrialsGov |
| dct:subject | dbc:Bromoarenes dbc:GABAA_receptor_positive_allosteric_modulators dbc:Methyl_esters dbc:Imidazobenzodiazepines dbc:2-Pyridyl_compounds |
| gold:hypernym | dbr:Drug |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatBenzodiazepines yago:Agent114778436 yago:Benzodiazepine102830852 yago:CausalAgent100007347 yago:Drug103247620 yago:DrugOfAbuse103248958 yago:Matter100020827 yago:Medicine103740161 yago:MinorTranquilizer103771443 yago:MuscleRelaxant103800001 yago:PhysicalEntity100001930 yago:PsychotropicAgent104017429 yago:Relaxant104072811 dbo:Drug yago:Sedative-hypnotic104166841 yago:Sedative104166553 yago:Substance100020090 yago:Tranquilizer104470232 |
| rdfs:comment | Remimazolam ist ein Arzneistoff aus der Gruppe der Benzodiazepine. Remimazolam wurde in Japan (als Anerem) im Januar 2020 zur allgemeinen Sedierung und in den USA und der EU (als Byfavo) im Juli 2020 bzw. März 2021 zur prozeduralen Kurzzeitsedierung (bei Verfahren, die bis zu 30 Minuten dauern) zugelassen. Es wird parenteral angewendet in Form des Benzolsulfonsäure-Salzes, Remimazolambesilat. (de) Ремимазолам — лекарственное средство группы бензодиазепинов. Одобрен для применения: Япония (2020), США (2020) (ru) Remimazolam, sold under the brand name Byfavo, is a medication for the induction and maintenance of procedural sedation in adults for invasive diagnostic or surgical procedures lasting 30 minutes or less. is a benzodiazepine drug, developed by in collaboration with several regional licensees as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in the induction of anesthesia and conscious sedation for minor invasive procedures. Remimazolam was found to have both a more rapid onset and a shorter duration than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications. (en) Il remimazolam è uno psicofarmaco appartenente alla categoria delle ; Il farmaco è stato sviluppato da PAION AG in collaborazione con diversi licenziatari regionali come alternativa al midazolam a breve durata d'azione, per l'uso nell'induzione dell'anestesia e nella sedazione cosciente per procedure invasive minori. È stato riscontrato che il remimazolam ha sia un inizio più rapido che una durata più breve rispetto al midazolam; inoltre studi clinici sull'uomo hanno mostrato un tempo di recupero più rapido e una farmacocinetica prevedibile e coerente, suggerendo alcuni vantaggi rispetto ai farmaci esistenti per queste applicazioni. (it) |
| rdfs:label | Remimazolam (de) Remimazolam (it) レミマゾラム (ja) Remimazolam (en) Ремимазолам (ru) |
| owl:sameAs | freebase:Remimazolam yago-res:Remimazolam wikidata:Remimazolam dbpedia-de:Remimazolam dbpedia-fa:Remimazolam dbpedia-it:Remimazolam dbpedia-ja:Remimazolam dbpedia-ru:Remimazolam dbpedia-sh:Remimazolam dbpedia-sr:Remimazolam https://global.dbpedia.org/id/4tTRd |
| prov:wasDerivedFrom | wikipedia-en:Remimazolam?oldid=1120555872&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Remimazolam.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Remimazolam |
| is dbo:wikiPageRedirects of | dbr:Byfavo dbr:Remimazolam_besylate |
| is dbo:wikiPageWikiLink of | dbr:List_of_benzodiazepines dbr:Byfavo dbr:SN_35210 dbr:Drugs_controlled_by_the_German_Betäubungsmittelgesetz dbr:AM-7438 dbr:ATC_code_N05 dbr:Retrometabolic_drug_design dbr:List_of_drugs:_Re dbr:Remimazolam_besylate |
| is foaf:primaryTopic of | wikipedia-en:Remimazolam |
